Figure 4
From: Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Initial versus final visual acuity in 141 eyes with documented visual acuity before and after treatment with ranibizumab. Group 1 comprises the eyes approved by the national health insurance system in Taiwan on only one application. Group 2 comprises the eyes approved on the second application (26 eyes) or third application (1 eye). (a) Scatter plot of initial versus final visual acuity. (b) Categorisation of visual improvement. (c) Categorisation of visual acuity as good (0.5–1.0), fair (0.2–0.4), and poor (0.01–0.1).
